Merck Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MERCK, and what generic alternatives to MERCK drugs are available?
MERCK has ninety-two approved drugs.
There are twenty-seven US patents protecting MERCK drugs.
There are seven hundred and forty-two patent family members on MERCK drugs in sixty-three countries and one hundred and eighty-one supplementary protection certificates in nineteen countries.
Summary for Merck
| International Patents: | 742 |
| US Patents: | 27 |
| Tradenames: | 77 |
| Ingredients: | 70 |
| NDAs: | 92 |
| Patent Litigation for Merck: | See patent lawsuits for Merck |
| PTAB Cases with Merck as patent owner: | See PTAB cases with Merck as patent owner |
Drugs and US Patents for Merck
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Kgaa | LEVOTHYROXINE SODIUM | levothyroxine sodium | TABLET;ORAL | 076752-006 | Jun 16, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-002 | Jan 19, 2021 | RX | Yes | No | 8,921,377 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck Sharp Dohme | CLARINEX | desloratadine | SOLUTION;ORAL | 021300-001 | Sep 1, 2004 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Merck Sharp Dohme | PREVYMIS | letermovir | TABLET;ORAL | 209939-002 | Nov 8, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Merck Sharp Dohme | STROMECTOL | ivermectin | TABLET;ORAL | 050742-002 | Oct 8, 1998 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Merck
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck | VIOXX | rofecoxib | TABLET;ORAL | 021042-003 | Feb 25, 2000 | 5,691,374*PED | ⤷ Sign Up |
| Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-002 | Jan 26, 2001 | 5,514,650*PED | ⤷ Sign Up |
| Merck Sharp Dohme | CLARINEX | desloratadine | SOLUTION;ORAL | 021300-001 | Sep 1, 2004 | 7,211,582*PED | ⤷ Sign Up |
| Merck | BLOCADREN | timolol maleate | TABLET;ORAL | 018017-004 | Approved Prior to Jan 1, 1982 | 3,655,663 | ⤷ Sign Up |
| Merck Sharp Dohme | REBETOL | ribavirin | CAPSULE;ORAL | 020903-002 | Jul 25, 2001 | 6,472,373*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MERCK drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2006-06-21 |
| ➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2010-10-18 |
| ➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-25 |
| ➤ Subscribe | Injection | 115 mg/vial | ➤ Subscribe | 2012-01-25 |
| ➤ Subscribe | for Oral Suspension | 125 mg/Kit | ➤ Subscribe | 2016-11-23 |
| ➤ Subscribe | Oral Solution | 70 mg/75 mL | ➤ Subscribe | 2007-09-07 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2011-02-28 |
| ➤ Subscribe | Injection | 18 mg/mL, 16.7 mL vials | ➤ Subscribe | 2015-11-24 |
| ➤ Subscribe | Orally Disintegrating Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2006-06-21 |
| ➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-19 |
| ➤ Subscribe | Capsule | 40 mg, 80 mg and 125 mg | ➤ Subscribe | 2008-11-03 |
| ➤ Subscribe | Tablets | 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg | ➤ Subscribe | 2012-11-06 |
| ➤ Subscribe | Injection | 150 mg/vial | ➤ Subscribe | 2012-01-25 |
| ➤ Subscribe | For Injection | 50 mg/vial and 70 mg/vial | ➤ Subscribe | 2009-06-26 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Capsules | 140 mg and 180 mg | ➤ Subscribe | 2008-03-24 |
| ➤ Subscribe | Delayed-release Tablets | 100 mg | ➤ Subscribe | 2014-06-16 |
International Patents for Merck Drugs
Supplementary Protection Certificates for Merck Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1441735 | C 2008 008 | Romania | ⤷ Sign Up | PRODUCT NAME: N-(2-(4-(4-FLUOROBENZILCARBAMOIL)-5-HIDROXI-1-METIL-6-OXO-1,6-DIHIDROPIRIMIDIN-2-IL)PROPAN-2+IL)-5-METIL-1,3,4-OXADIAZOL-2-CARBOXAMIDA - RALTEGRAVIR SAU O SARE ACCEPTABILAFARMACEUTIC A ACESTUIA, INSPECIAL SAREA DE POTASIU; NATIONAL AUTHORISATION NUMBER: EMEA EU/1/07/436/001, EMEA EU/1/07/436/002; DATE OF NATIONAL AUTHORISATION: 20071220; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/07/436/001, EMEA EU/1/07/436/002; DATE OF FIRST AUTHORISATION IN EEA: 20071220 |
| 1441735 | 67 3-2008 | Slovakia | ⤷ Sign Up | PRODUCT NAME: RALTEGRAVIR; REGISTRATION NO/DATE: EU/1/07/436/001 - EU/1/07/436/002 20080102 |
| 3494972 | LUC00346 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, Y COMPRIS LE DOLUTEGRAVIR SODIQUE, ET LAMIVUDINE; AUTHORISATION NUMBER AND DATE: EU/1/19/1370 20190703 |
| 0443983 | C00443983/03 | Switzerland | ⤷ Sign Up | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
| 0720599 | SPC/GB05/010 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
